TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028 Credit facility anticipated to fund development of pipeline, including IFx-2.0 through Phase 3 results and TBS-2025 to key efficacy…...

TuHURA Bio signs royalty loan agreement for up to $50mm
*Funded by K&V Investment One affiliate
*12% interest rate
*5 year maturity
*1-5% royalty on IFx-2.0 products
$HURA
ir.tuhurabio.com/news-events/...

Spectral AI 2026 Revenue Breakdown YouTube video by Unboxing Biotech

Spectral AI’s CEO Vincent Capone provides the detail behind its 2026 revenue forecast including a small contribution from product sales.
youtube.com/shorts/P9ShB...
$MDAI #MedicalAI #MedTech #LifeSciences #Biotech #MedicalDevices #DiagnosticTools

Ligand to Report First Quarter 2026 Financial Results on May 7, 2026 JUPITER, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026. ...

Ligand Pharmaceuticals to report 1Q26 on 7May
*Call @ 8:30 am ET
*Dial-in details in PR
$LGND
finance.yahoo.com/markets/stoc...

Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026 SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announce...

Cardiff Oncology to present updated Ph2 data @ ASCO
*Interim results
*Available 21May
$CRDF
finance.yahoo.com/sectors/heal...

Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales 600,000 New Wegovy® Pill Prescriptions Written in First Two Months KELOWNA, BC / ACCESS Newswire / April 21, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innov...

Lexaria Bioscience highlights the importance of the GLP-1 class in a press release
*Growth is expected from oral forms
*Oral could be >17% of market
*Sales forecasts increasing
*$LEXX DehydraTECH may benefit from this trend
finance.yahoo.com/sectors/heal...

Spectral AI Announces Annual Meeting of Stockholders DALLAS, April 20, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more...

Spectral AI announced its 2026 annual meeting of stockholders set for:
Friday, May 29 at 9:30 am CT.
$MDAI
finance.yahoo.com/markets/stoc...

Metabo Oncology Origins YouTube video by Unboxing Biotech

SynDevRx Chief Business Officer Jim Shanahan shares the origins of Metabo-Oncology.
youtube.com/shorts/CwA7_...
#SyntheticBiology #DrugDiscovery #PrecisionMedicine #GenomicsResearch #BioInformatics #ClinicalResearch #LifeSciences #BiotechInnovation

SynDevRx Chief Business Officer Jim Shanahan lists the rationale behind selecting evexomostat as the company’s lead candidate.
#SyntheticBiology #DrugDiscovery #LifeSciences #BiotechInnovation #BiotechInvestor #HealthcareInvesting #VentureCapital #BioTechStartup #HealthTech #MedTech #BioPharma

Chelsea Luxen @ ParaNano YouTube video by Unboxing Biotech

John Vandermosten presents ParaNano's CEO Chelsea Luxen in our full episode as we look at unmet needs in wound care, the WoundCue bandage & Bio-Z technology which provides a platform for a variety of wound care products.
youtu.be/8cEZxKCG_fU
#MedTech #SmartBandage #InfectionDetection

Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026 177Lu-RAD202 demonstrated encouraging tumor uptake and a favorable safety profile in the lowest dose cohort Data Safety and Monitoring Committee Recently Approved Advancing 177Lu-RAD202 to Next Highes...

Radiopharm Theranostics presents initial findings for RAD202 @theaacr.bsky.social
*20Apr in San Diego
*Enters 3rd cohort @ 130mCi dosing
*Meaningful tumor uptake
*Well tolerated
*Poster on website
$RADX
finance.yahoo.com/sectors/heal...

Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting Onvansertib in combination with trastuzumab deruxtecan demonstrated enhanced antitumor activity, including tumor regression and apoptosis in HER2-low breast cancer models, supporting its potential for...

Cardiff Oncology to present preclinical onvansertib data @theaacr.bsky.social in breast cancer.
*In combination with HER2 ADC
*Murine model shows up to 62% CR rate
*Presentation on 19Apr
*Poster available on $CRDF website
finance.yahoo.com/sectors/heal...

BARDA Commercialization Support YouTube video by Unboxing Biotech

Spectral AI’s BARDA contract supports the deployment of the DeepView Burn diagnostic following FDA approval. $MDAI CEO Vincent Capone elaborates on the device’s deployment plans.
#HealthTech #MedTech #LifeSciences #Biotech #MedicalDevices #DiagnosticTools
youtube.com/shorts/kVmXp...

Achieve appoints Andrew Goldberg as CEO & board member along with 2 other board members.
achievelifesciences.com/achieve-appo...
$ACHV also to raise $180mm private placement w/ another $174mm available from warrants from a group of recognized investors.
achievelifesciences.com/achieve-anno...

Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases Interim data to date showed 90% concordance with MRI (the primary endpoint) Clinical trial readout (Primary endpoint) expected in June 2026 Plans to advance RAD 101 into U.S. Phase 3 pivotal trial SYD...

Radiopharm Theranostics completes Ph2b RAD101 enrollment for imaging brain metastases.
Readout expected in June.
$RADX focus turns to Ph3 preparations.
finance.yahoo.com/sectors/heal...
Zacks' RAD101 report: s27.q4cdn.com/906368049/fi...

GeoVax Reports 2025 Year-End Financial Results and Provides Business Update Pivotal Phase 3 Trial for GEO-MVA (Mpox/Smallpox Vaccine) Scheduled to Initiate During the Second Half of This Year ATLANTA, GA - April 15, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a cl...

GeoVax reports 2025 results.
Ph3 GEO-MVA study to launch 2H26.
10-K filed.
$GOVX
finance.yahoo.com/sectors/heal...

Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions Adare Partnership Provides Supply Chain Redundancy and U.S.-based Manufacturing Capability Company Reiterates Guidance - If Approved, Cytisinicline Commercial Launch Expected in First Half of 2027 SEA...

Achieve Life Sciences transferred cytisinicline manufacturing to Ohio-based Adare Pharma Solutions.
$ACHV expects a CRL for cytisinicline & a delay from its 20Jun PDUFA date. NDA resubmission with Adare expected in 4Q26 & 1H27 launch.
finance.yahoo.com/sectors/heal...

BARDA Award YouTube video by Unboxing Biotech

Spectral AI CEO Vincent Capone gives background on the $32 million BARDA award which will help advance DeepView Burn. Supported initiatives include EHR integration, total body surface area (TBSA) measurement & further enhancements of the AI algorithm.
$MDAI
youtube.com/shorts/vfsQB...
#MedTech

Reviva Announces Letter to Shareholders - Reviva Pharmaceuticals CUPERTINO, Calif., April 15, 2026 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapi...

Reviva Pharmaceuticals' CEO Dr Bhat pens shareholder letter
*$23mm in cash to support RECOVER2 patient enrollment 3Q26
*New brilaroxazine formulation may extend IP
$RVPH
revivapharma.com/reviva-annou...
#schizophrenia #ClinicalTrials #Biotech #Pharma

FDA approves Travere's Filspari for FSGS. Ligand Pharma receives a 9% royalty on Filspari. The FSGS indication has twice the dose as the already approved IgA nephropathy, providing substantially more upside.
$LGND $TVTX
ir.travere.com/press-releas...

Clinical Trial Confidence YouTube video by Unboxing Biotech

Spectral AI CEO Vincent Capone speaks with us about recent clinical trials & the performance of the DeepView Burn diagnostic in predicting healing tissue.
$MDAI
#MedTech #HealthTech #LifeSciences #MedicalDevices
youtube.com/shorts/YsI7X...

Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive OfficerAppoints industry veterans Josh Muntner as Chief Financial Officer and Ajay Aggarwal, MD, MBA, as Chief Oper...

Cardiff Oncology appoints Dr Mani Mohindru as permanent CEO. New executive appointments include Josh Muntner as CFO & Ajay Aggarwal as COO.
$CRDF
finance.yahoo.com/sectors/heal...

Network of Angel Investors YouTube video by Unboxing Biotech

ParaNano’s CEO, Chelsea Luxen, looks at the finance side of things highlighting the network of angel investors that have supported the company & looking ahead to future needs and milestones.
youtube.com/shorts/g7jth...
#MedTech #SmartBandage #InfectionDetection #MedTechInnovation

Spectral AI to Feature DeepView® System at 2026 American Burn Association Annual Meeting DeepView System will be on Display at Booth #601DALLAS, April 09, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company fo...

Spectral AI to present its DeepView Burn diagnostic @ the American Burn Association meeting April 14-17 in Orlando.
*Hands on demonstration
*Overview with Chris Lewis www.youtube.com/watch?v=FJ-Y...
$MDAI
finance.yahoo.com/sectors/heal...

MDAI FDA Expectations YouTube video by Unboxing Biotech

Spectral AI CEO Vincent Capone discusses the company's interactions with the FDA and looks ahead towards a response from the agency by the end of 2Q:26.
$MDAI
youtube.com/shorts/CI8Oy...
#Biotech #MedicalDevices #DiagnosticTools

Spectral AI Names David McGuire, CPA, as Chief Financial Officer DALLAS, April 08, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more...

Spectral AI appoints David McGuire as CFO.
Previously at Solo Brands, EZCORP & E&Y.
Effective 4May26.
$MDAI
finance.yahoo.com/sectors/heal...

Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to progress Phase 1 to the next dose level of 130mCi in patients with HER2+ advanced solid tumorsSYDNEY, April 08, 202...

Radiopharm Theranostics gets go ahead from DSMC to advance to 130mCi in the Ph1 RAD202 trial.
*HER2+ tumors
*Dose escalation done by end of '26
$RADX
finance.yahoo.com/sectors/heal...

ParaNano Purchase Orders YouTube video by Unboxing Biotech

ParaNano’s CEO, Chelsea Luxen, highlights 2 purchase orders for WoundCue with Veteran's Way, who sells into the VA & Bethany Children's Health Center, which is the clinical site for the trial.
youtube.com/shorts/JXftq...
#MedTech #SmartBandage #InfectionDetection #ChronicWounds #WoundManagement

TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced Aman...

TuHURA Bio appoints Amanda Garofalo as SVP of operations.
$HURA
finance.yahoo.com/sectors/heal...

Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S. Data from the interim analysis in Phase 2b trial of RAD101 showed significant and selective tumor uptake in brain metastases, with 90% concordance (Primary Endpoint) with MRI. Partnership ensures suff...

Radiopharm Theranostics pens agreement with Siemens Healthineers.
Siemens will radiolabel & distribute F-18 RAD101 in US for Ph3 trial.
$RADX
finance.yahoo.com/sectors/heal...
Our RAD101 clinical update: s27.q4cdn.com/906368049/fi...